Valencia is better known for Six Flags than surgical breakthroughs, but SetPoint Medical just turned this quiet California zip code into a frontline in the war against autoimmune disease. On August 11, 2025, the company announced $140 million in private financing, split between a $25 million Series C tranche and a $115 million Series D. Elevage Medical Technologies and Ally Bridge Group co-led the round, flanked by new investors Northwell Health, SPRIG Equity, and a strategic player keeping its name close to the vest. Heavy-hitters like Norwest Venture Partners, New Enterprise Associates, Viking Global Investors, Action Potential Venture Capital, Abbott, and Boston Scientific doubled down. You do not get that investor table without a serious hand to play.
The play here is not another pill or injection. It is a device, an implantable, rechargeable neurostimulation system that targets the vagus nerve like a scalpel made of code and current. Daily, precise pulses activate the body’s own inflammatory reflex, calming overactive immune systems without blunting their defense. Think of it as teaching your body not to burn the house down just to kill a mosquito. The FDA approved the SetPoint System on July 31, 2025, off the strength of the RESET-RA trial: 242 participants, statistically significant results, and three out of four patients free of biologics or targeted synthetic DMARDs after a year. Safety profile? 1.7% serious adverse events, with zero malignancies, cardiac events, or serious infections.
That is not just a win for SetPoint Medical; it is a paradigm shift for rheumatoid arthritis treatment, with eyes already on multiple sclerosis and Crohn’s disease. The market runway is long, $30 billion and growing at a 5.58% CAGR through 2031. Murthy V. Simhambhatla, Ph.D., the CEO since 2018, knows how to scale regulated medtech, his Evolus IPO track record is proof. With CMO David Chernoff, CFO Rohan Seth, and new commercial leadership in Erik Styacich and Spencer Bailey, the infrastructure is being built for a targeted U.S. launch this year and national expansion in early 2026.
Founders James Broderick, Dr. Kevin J. Tracey, and Dr. H. Shaw Warren took a bet in 2007 that bioelectronic medicine could move from whiteboard to operating room. Eighteen years later, with FDA clearance, deep-pocketed backers, and a tech platform that runs on electricity instead of pharmaceuticals, SetPoint Medical is about to see if the market believes it too. In poker terms, the company just pushed a stack the size of Valencia across the table. Now the industry waits to see who calls.
